(Q36726461)

15 August 2017

1 reference

title

Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer (English)

1 reference

15 August 2017

main subject

cervix uterine cancer

1 reference

Wu TC

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

European Journal of Immunology

15 August 2017

published in

1 reference

15 August 2017

volume

37

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

310-314

1 reference

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

How will HPV vaccines affect cervical cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

DNA vaccines: immunology, application, and optimization*

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Cell biology of antigen processing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

DNA vaccine using invariant chain gene for delivery of CD4+ T cell epitope peptide derived from Japanese cedar pollen allergen inhibits allergen-specific IgE response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Cooperation between CD4+ and CD8+ T cells: when, where, and how.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636978

7 January 2021

Identifiers

DOI

10.1002/EJI.200636978

1 reference

15 August 2017

1 reference